S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
The single greatest medical breakthrough of all time? (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
The single greatest medical breakthrough of all time? (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
The single greatest medical breakthrough of all time? (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
The single greatest medical breakthrough of all time? (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
NASDAQ:VERU

Veru - VERU Stock Forecast, Price & News

$5.50
+0.02 (+0.36%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.40
$5.63
50-Day Range
$5.35
$15.01
52-Week Range
$4.34
$24.55
Volume
2.91 million shs
Average Volume
8.01 million shs
Market Capitalization
$440.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00

Veru MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
518.2% Upside
$34.00 Price Target
Short Interest
Bearish
24.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of Veru in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.85) to ($0.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

459th out of 1,034 stocks

Pharmaceutical Preparations Industry

203rd out of 502 stocks

VERU stock logo

About Veru (NASDAQ:VERU) Stock

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Stock News Headlines

Is Veru a Buy?
Is It Too Late to Buy Veru Stock?
Why Shares of Veru Fell 10.33% on Monday
Why Veru Stock Was Losing One-Third of Its Value This Week
Why Veru Stock Is Cratering Today
UPDATE 3-U.S.FDA panel votes against Veru's COVID-19 pill
See More Headlines
Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Company Calendar

Last Earnings
12/02/2021
Today
12/04/2022
Next Earnings (Estimated)
12/05/2022
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
Sector
Medical
Current Symbol
NASDAQ:VERU
CUSIP
31446210
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$34.00
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+518.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$7.39 million
Pretax Margin
-90.02%

Debt

Sales & Book Value

Annual Sales
$61.26 million
Book Value
$1.91 per share

Miscellaneous

Free Float
61,633,000
Market Cap
$440.83 million
Optionable
Optionable
Beta
-0.33

Key Executives

  • Dr. Mitchell S. Steiner F.A.C.S (Age 61)
    F.A.C.S., M.D., Chairman, Pres & CEO
    Comp: $1.43M
  • Dr. Harry Fisch F.A.C.S. (Age 63)
    M.D., Vice Chairman & Chief Corp. Officer
    Comp: $648.12k
  • Ms. Michele Greco (Age 63)
    CFO & Chief Admin. Officer
    Comp: $659.62k
  • Dr. K. Gary Barnette Ph.D. (Age 54)
    Chief Scientific Officer
    Comp: $636.7k
  • Mr. Samuel Fisch
    Exec. Director of Investor Relations & Corp. Communications
  • Mr. Michael J. Purvis
    Exec. VP, Gen. Counsel & Corp. Strategy and Sec.
  • Mr. Kevin J. Gilbert CPA
    J.D., Exec. VP of Corp. Devel.
  • Dr. Domingo Rodriguez M.D. (Age 60)
    Exec. VP of Global Clinical Operations
  • Dr. Gary Bird Ph.D.
    Exec. VP of Quality & Regulatory Affairs
  • Mr. Joel Batten
    Exec. VP & GM of Infectious Disease Franchise













VERU Stock - Frequently Asked Questions

Should I buy or sell Veru stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VERU shares.
View VERU analyst ratings
or view top-rated stocks.

What is Veru's stock price forecast for 2023?

5 brokerages have issued 1 year price objectives for Veru's stock. Their VERU share price forecasts range from $21.00 to $55.00. On average, they expect the company's share price to reach $34.00 in the next twelve months. This suggests a possible upside of 518.2% from the stock's current price.
View analysts price targets for VERU
or view top-rated stocks among Wall Street analysts.

How have VERU shares performed in 2022?

Veru's stock was trading at $5.89 on January 1st, 2022. Since then, VERU stock has decreased by 6.6% and is now trading at $5.50.
View the best growth stocks for 2022 here
.

When is Veru's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, December 5th 2022.
View our VERU earnings forecast
.

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) released its earnings results on Thursday, December, 2nd. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.04. The firm earned $15.65 million during the quarter, compared to analyst estimates of $18.26 million. Veru had a negative trailing twelve-month return on equity of 34.02% and a negative net margin of 89.77%. During the same period in the previous year, the company earned ($0.01) earnings per share.

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), OrganiGram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

Who are Veru's major shareholders?

Veru's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.31%), Perceptive Advisors LLC (4.86%), Vanguard Group Inc. (3.88%), Boxer Capital LLC (3.12%), Citadel Advisors LLC (0.00%) and Jane Street Group LLC (0.00%). Insiders that own company stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Lucy Lu, Mario Eisenberger, Michele Greco and Mitchell Shuster Steiner.
View institutional ownership trends
.

How do I buy shares of Veru?

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $5.50.

How much money does Veru make?

Veru (NASDAQ:VERU) has a market capitalization of $440.83 million and generates $61.26 million in revenue each year. The company earns $7.39 million in net income (profit) each year or ($0.59) on an earnings per share basis.

How many employees does Veru have?

The company employs 252 workers across the globe.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The official website for the company is www.veruhealthcare.com. The company can be reached via phone at (305) 509-6897, via email at veruinvestor@verupharma.com, or via fax at 312-595-9122.

This page (NASDAQ:VERU) was last updated on 12/4/2022 by MarketBeat.com Staff